|
Colorectal Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Functional studies determined the interaction between LINC01555 and NmU in the development of CRC.
|
31144675 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.010 |
Biomarker
|
disease |
BEFREE |
Serum NMU is not a human decretin hormone and may not play a role in the pathogenesis of T2DM.
|
31004673 |
2019 |
|
Secondary malignant neoplasm of pancreas
|
0.010 |
Biomarker
|
disease |
BEFREE |
These results indicate that the identified positive correlation between YAP1 and NMU is a potential novel drug target and biomarker in metastatic pancreatic cancer.
|
31575084 |
2019 |
|
Secondary Neoplasm
|
0.010 |
AlteredExpression
|
group |
BEFREE |
YAP1 overexpression induced NMU expression and transcription and promoted cell motility in vitro and tumor metastasis in vivo via upregulation of epithelial-mesenchymal transition (EMT), whereas specific inhibition of NMU in cells stably expressing YAP1 had the opposite effect in vitro and in vivo.
|
31575084 |
2019 |
|
Amnesia
|
0.010 |
Biomarker
|
disease |
BEFREE |
In order to utilize NMU as a clinical treatment tool for inflammation-mediated amnesia, we herein focused on non-invasive intranasal delivery because the i.c.v. administration route is invasive and impractical.
|
29079533 |
2018 |
|
Osteosarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Functional terms (potassium ion transport, transmembrane transporter activity, and neuroactive ligand‑receptor interaction) and hub genes (NMU and NMUR1) may serve as potential targets for the treatment and diagnosis of OS.
|
29115427 |
2018 |
|
Memory impairment
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Moreover, the administration of PASR8-NMU or F4R8-NMU (5.6μg/mouse, i.n.) just before the Y-maze test also improved LPS-induced memory impairment.
|
29079533 |
2018 |
|
Non-alcoholic Fatty Liver Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
These data indicate a novel role for the peripheral NMU system, providing new insights into the pathogenesis of NAFLD/NASH.
|
29017855 |
2018 |
|
Endometrial Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Long non-coding RNA HAND2-AS1 inhibits invasion and metastasis in endometrioid endometrial carcinoma through inactivating neuromedin U.
|
29107108 |
2018 |
|
Forgetful
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Moreover, the administration of PASR8-NMU or F4R8-NMU (5.6μg/mouse, i.n.) just before the Y-maze test also improved LPS-induced memory impairment.
|
29079533 |
2018 |
|
Osteosarcoma of bone
|
0.010 |
Biomarker
|
disease |
BEFREE |
Functional terms (potassium ion transport, transmembrane transporter activity, and neuroactive ligand‑receptor interaction) and hub genes (NMU and NMUR1) may serve as potential targets for the treatment and diagnosis of OS.
|
29115427 |
2018 |
|
Dystonia, Secondary
|
0.010 |
Biomarker
|
disease |
BEFREE |
Nine Children with severe secondary dystonia underwent the NMU targeting procedure.
|
30018276 |
2018 |
|
Childhood Osteosarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Functional terms (potassium ion transport, transmembrane transporter activity, and neuroactive ligand‑receptor interaction) and hub genes (NMU and NMUR1) may serve as potential targets for the treatment and diagnosis of OS.
|
29115427 |
2018 |
|
ECTRODACTYLY, ECTODERMAL DYSPLASIA, AND CLEFT LIP/PALATE SYNDROME 1
|
0.010 |
Biomarker
|
disease |
BEFREE |
Furthermore, the anti-tumorigenic effect of HAND2-AS1 was mediated by down-regulating NMU, which has an oncogenic role in EEC.
|
29107108 |
2018 |
|
Nonalcoholic Steatohepatitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Role of neuromedin U in accelerating of non-alcoholic steatohepatitis in mice.
|
29017855 |
2018 |
|
Fatty Liver Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
Furthermore, overproduction of NMU induced the mouse liver by hydrodynamic injection, exacerbated NASH pathogenesis.
|
29017855 |
2018 |
|
Pituitary Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
Neuromedin U (NMU) is a neuropeptide known to regulate food intake and energy homeostasis that is widely distributed in the gastrointestinal tract, hypothalamus, and pituitary.
|
28291683 |
2017 |
|
Central Serous Chorioretinopathy
|
0.010 |
Biomarker
|
disease |
BEFREE |
Taken together, our results report a new mechanism of action for NmU in HER2-overexpressing breast cancer that enhances resistance to HER2-targeted drugs through conferring CSC characteristics and expansion of the CSC phenotype.
|
28340506 |
2017 |
|
winter depression
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, the excessive synthesis of melatonin during the autumn and winter may negatively affect the expression of neuromedin U in the pars tuberalis, causing an increased appetite, which is common in winter depression patients.
|
28012610 |
2017 |
|
Mammary Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Using an in silico dataset comprising 1,195 samples, high NMU expression was identified as an indicator of poor outcome in breast tumors showing strong NMUR2 expression.
|
28423716 |
2017 |
|
Hyperactive behavior
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
We found that the neuropeptide neuromedin U (Nmu) promotes hyperactivity and inhibits sleep in zebrafish larvae, whereas nmu mutant animals are hypoactive.
|
26889812 |
2016 |
|
Kidney Neoplasm
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Our study raises the possibility that HIF may also drive NMU expression in non-renal tumours.
|
21791076 |
2011 |
|
Malignant neoplasm of kidney
|
0.010 |
Biomarker
|
disease |
BEFREE |
These findings suggest that NMU may act in an autocrine fashion, promoting progression of kidney cancer.
|
21791076 |
2011 |
|
Renal carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
These findings suggest that NMU may act in an autocrine fashion, promoting progression of kidney cancer.
|
21791076 |
2011 |
|
Adenocarcinoma of lung (disorder)
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
SPP1 skeletal development module appears in human normal adjacent tissues (COL11A1_1 activation; COL10A1 inhibition), whereas in lung adenocarcinoma (COL11A1_2, COL1A2 activation); signal module appears in human normal adjacent tissues (COL11A1_1, CXCL13, MMP11, SPINK1 activation; COL10A1, COL3A1 inhibition), whereas in lung adenocarcinoma (COL11A1_2, COL1A2, MMP12 activation; CDH3, CXCL13, GREM1_2, MMP11, SPINK1 inhibition); biological regulation module appears in human normal adjacent tissues (CXCL13, MKI67, PYCR1 activation; NEK2, SPDEF, TOP2A_2, TOX3_1 inhibition), whereas in lung adenocarcinoma (HMGB3, MKI67, NMU, PYCR1, TOX3_2 activation; CXCL13, SPDEF, TOP2A_2 inhibition); sequence variant module appears in human normal adjacent tissues (COL11A1_1, MKI67, MMP11 activation; ASPM, COL10A1, COL3A1, NEK2, TMPRSS4, TOP2A_2 inhibition), whereas in lung adenocarcinoma (COL11A1_2, COL1A2, HMMR, MKI67, MMP12 activation; ABCC3, ASPM, CDH3, MMP11, TOP2A_2 inhibition).
|
19949890 |
2010 |